Maprotiline
Ludiomil (maprotiline) is a small molecule pharmaceutical. Maprotiline was first approved as Ludiomil on 1982-01-01. It is used to treat bipolar disorder, bulimia, cocaine-related disorders, duodenal ulcer, and dysthymic disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, transient receptor potential cation channel subfamily M member 3, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
| chemically-induced disorders | D064419 |
| behavior and behavior mechanisms | D001520 |
| psychological phenomena | D011579 |
| mental disorders | D001523 |
| musculoskeletal and neural physiological phenomena | D055687 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maprotiline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUDIOMIL | Novartis | N-017543 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| bulimia | — | D002032 | F50.2 |
| cocaine-related disorders | — | D019970 | F14 |
| duodenal ulcer | EFO_0004607 | D004381 | K26 |
| dysthymic disorder | EFO_0008623 | D019263 | F34.1 |
| enuresis | — | D004775 | R32 |
| pain | EFO_0003843 | D010146 | R52 |
| panic disorder | EFO_0004262 | D016584 | F41.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | — | — | — | 1 | 1 |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MAPROTILINE |
| INN | maprotiline |
| Description | Maprotiline, sold under the brand name Ludiomil among others, is a tetracyclic antidepressant (TeCA) that is used in the treatment of depression. It may alternatively be classified as a tricyclic antidepressant (TCA), specifically a secondary amine. In terms of its chemistry and pharmacology, maprotiline is closely related to other secondary amine TCAs like nortriptyline and protriptyline, and has similar effects to them.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNCCCC12CCC(c3ccccc31)c1ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 10262-69-8 |
| RxCUI | 6646 |
| ChEMBL ID | CHEMBL21731 |
| ChEBI ID | 6690 |
| PubChem CID | 4011 |
| DrugBank | DB00934 |
| UNII ID | 2U1W68TROF (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
KCNJ6
KCNJ6
TRPM3
TRPM3
KCNJ5
KCNJ5
Organism
Homo sapiens
Gene name
KCNJ6
Gene synonyms
GIRK2, KATP2, KCNJ7
NCBI Gene ID
Protein name
G protein-activated inward rectifier potassium channel 2
Protein synonyms
BIR1, Inward rectifier K(+) channel Kir3.2, inward rectifier potassium channel KIR3.2, KATP-2, Potassium channel, inwardly rectifying subfamily J member 6, potassium channel, inwardly rectifying subfamily J, member 6, potassium voltage-gated channel subfamily J member 6
Uniprot ID
Mouse ortholog
Kcnj6 (16522)
G protein-activated inward rectifier potassium channel 2 (P48542)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,733 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more